Corporation (NYSE:ECOM), a leading provider of cloud-based e-commerce
solutions that enable retailers and manufacturers to increase global
sales, today announced the acquisition of E-Tale Holdings Limited, a
UK-based company that offers a leading global “Where to Buy” solution.
Kemper Corporation (NYSE: KMPR)
reported today net income of $4.7 million, or $0.09 per diluted share,
for the third quarter of 2014, compared to $70.1 million, or $1.23 per
diluted share, for the third quarter of 2013.
Display Corporation (Nasdaq: OLED), enabling energy-efficient
displays and lighting with its UniversalPHOLED ®
technology and materials, today reported financial results for the third
quarter ended September 30, 2014.
Technology Growth Capital, Inc. (NYSE: HTGC) (“Hercules” or the
“Company”), the leading specialty finance company focused on providing
senior secured loans to venture capital-backed companies in
technology-related markets, including technology, biotechnology, life
science, and energy & renewable technology industries, at all stages of
development, announced today its financial results for the third quarter
ended September 30, 2014.
ORBCOMM Inc. (Nasdaq:ORBC), a leading global provider of
Machine-to-Machine (M2M) solutions, announced today an underwritten
registered public offering (the “Offering”), subject to market and other
conditions, of its shares of common stock, par value $0.001 per share,
up to an aggregate sales price of $72 million.
ICF International, Inc. (NASDAQ:ICFI), a leading provider of consulting
services and technology solutions to government and commercial clients,
reported results for the third quarter ended September 30, 2014.
Conference Call and Webcast Today, November 6, at 4:30 p.m. ET
Recent Business Highlights
Submitted a supplemental New Drug Application (sNDA) for a modified formulation with potential abuse deterrent properties of Zohydro ® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, on September 30, with a target action date in late January 2015
Acquired Brabant Pharma, obtaining global rights for a Phase 3 product candidate with orphan drug designation in the U.S. and Europe for the treatment of Dravet syndrome
Exchanged waivers of regulatory exclusivity for extended-release hydrocodone products with Purdue Pharma, which includes $10 million in payments and potential sales royalties from Purdue
Signed a non-binding term sheet that is anticipated to provide a $20 million term loan plus an additional $4 million in a revolving line of credit Third Quarter 2014 Highlights
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.